Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Tatiana Molostova (Moscow, Russian Federation), Tatiana Molostova, Alexander Chuchalin, Sofia Skachilova, Elena Shilova, Yuriy Kalinin, Tamerlan Balaev, Irina Badygina, Alexander Solovyev. Bronchodilator activity of the combination of salbutamol hemisuccinate and methatropium iodide compared with monotherapy in preclinical studies. Eur Respir J 2015; 46: Suppl. 59, 3958

Member's Comments

No comment yet.

Related content which might interest you: Interaction between aclidinium bromide and formoterol fumarate; effects on human bronchial smooth muscle Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Pharmacological interaction between glycopyrronium bromide and indacaterol fumarate on the human airways tone Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016 The dual PDE3/PDE4 phosphodiesterase inhibitor RPL554 produces more complete bronchodilator responses than the beta2-agonist salbutamol and the anti-muscarinic agent ipratropium bromide, alone and in combination, in guinea-pig isolated trachea Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 The combination therapy with inhaled tiotropium bromide and indacaterol in COPD improves the peripheral airway function in static and dynamic status Source: International Congress 2014 – Asthma and COPD management Year: 2014 Pharmacological characterization of the mechanism of action leading to synergism between glycopyrronium bromide and indacaterol fumarate Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016 Interaction between aclidinium bromide and formoterol fumarate in small human airways Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Combination study of tiotropium and olodaterol in human precision-cut lung slices Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 Endothelin-1-mediated contraction of mouse small airways is resistant to salbutamol, but sensitive to rosiglitazone Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 Interaction between RPL554 and glycopyrronium bromide in small human airways Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 A comparison of beta2-adrenoceptor desensitisation induced by olodaterol and formoterol in human lung mast cells and airway smooth muscle cells Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 Long-lasting interaction study between RPL554 and glycopyrronium bromide on human isolated bronchi Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Pharmacologic bronchodilation response to salbutamol in COPD patients Source: International Congress 2014 – Predictors Year: 2014 Inhaled roflumilast and tadalafil supress airway reactivity and inflammation in ovalbumin-sensitized guinea pigs Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016 Abediterol has higher bronchodilatory potency and reduced cardiac effects versus other long-acting beta2-agonists in dogs Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 Once-daily QVA149 improves lung function and dyspnoea compared with tiotropium plus formoterol: The QUANTIFY study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Effectiveness of glycopyrronium bromide in the treatment of small airways dysfunction Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Effect of the once-daily long-acting bronchodilator combination umeclidinium/vilanterol (UMEC/VI) and bronchodilator monotherapy on dyspnoea as measured by the transitional dyspnoea index (TDI) in COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Rapid corticosteroid effect on long-acting β2-agonist disposal by smooth muscle cells in the airway: a new paradigm of inhaled combination therapy Source: Eur Respir Rev 2008; 17: 41-42 Year: 2008 Rapid corticosteroid effect on long-acting β2-agonist disposal by smooth muscle cells in the airway: a new paradigm of inhaled combination therapy Source: Eur Respir J 2007; 30: Suppl. 51, 713s Year: 2007 Tiotropium respimat: Comparison of bronchodilator efficacy of 5 and 2.5 µg doses Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014